SimplicityDx Panel FluA/FluB/RSV

Molecular Designs wins FDA clearance for FluA/FluB/RSV panel

Image
Molecular Designs wins FDA clearance for FluA/FluB/RSV panel

BIRMINGHAM -- November 16, 2026 -- Molecular Designs has received U.S. FDA 510(k) clearance (K262789) for its SimplicityDx Panel FluA/FluB/RSV, the first FDA-cleared assay from the Alabama-based company, it announced on Nov. 13, 2026. The multiplex real-time RT-PCR test detects and differentiates influenza A, influenza B and respiratory syncytial virus (RSV) RNA in anterior nasal swab specimens in a single run, with an internal control as a fourth target.

Clearance limits the panel to CLIA high-complexity laboratories

The panel is for prescription use only. It is cleared for laboratories certified under CLIA to perform high-complexity tests, so labs without that certification fall outside the cleared use.

The specimens come from individuals with signs and symptoms of respiratory tract infection. Results are intended as an aid in differential diagnosis, alongside clinical, epidemiologic and laboratory findings.